VNRX vs GKOS

For growth investors, VolitionRx Limited (VNRX) is the stronger pick with 40.

0% revenue growth year-over-year, versus 32. 3% for Glaukos Corporation (GKOS). Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.

5%, compared to -96. 1% for VolitionRx Limited (VNRX). Over 10 years, the gap is even starker: GKOS returned +457. 1% versus VNRX's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), VolitionRx Limited (VNRX) is the lower-risk stock at 0.

17β versus Glaukos Corporation's 1. 20β — meaning GKOS is approximately 588% more volatile than VNRX relative to the S&P 500.

By revenue growth (latest reported year), VolitionRx Limited (VNRX) is pulling ahead at 40.

0% versus 32. 3% for Glaukos Corporation (GKOS). On earnings-per-share growth, the picture is similar: VolitionRx Limited grew EPS 29. 0% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, VNRX leads at 78. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Glaukos Corporation (GKOS) is the more profitable company, earning -37.

0% net margin versus -1352. 2% for VolitionRx Limited — meaning it keeps -37. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GKOS leads at -17. 1% versus -1228. 6% for VNRX. At the gross margin level — before operating expenses — VNRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, VolitionRx Limited (VNRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

17)). Both have compounded well over 10 years (VNRX: -96. 2%, GKOS: +457. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.